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ABSTRACT
One in every eight women worldwide will be diagnosed to be suffering with breast cancer in their lifetime. It is vital not only to 
diagnose the disease early but also to refer it to a tertiary care center for the most appropriate or standard anti-cancer treatment without 
delay. The outcomes of such therapy can be a game changer for the patient. Screening mammography is only having a small reduction 
in mortality of breast cancer. Here, we present a clinical report of one patient who had Her2 Neu positive disease with early central 
nervous system (CNS) metastasis and responded extremely well to anti her2 Neu therapy with chemotherapy and has survived over 
six years now on treatment.
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Worldwide around 14 million new cancer cases were diagnosed in 2012 according to GLOBOCAN data [1]. So, out of 7.6 billion or 7600 million world 
population 5.42 % developed cancer annually. Over 60% of these 
cases were from under developed or developing world. Every year 
cancer kills over 8.2 million people globally. Notably ischemic 
heart disease has killed 8.8 million worldwide at the same time. 
After lung, liver, colon and stomach cancer, breast cancer is the 
fifth leading cause of, cancer related death worldwide. Annually, 
approximately 1.7 million new breast cancer cases are recorded 
with 99% being women.
Metastasis in breast cancer can occur at any stage of its natural 
history, with 5% being metastatic at presentation. The expression 
of a transmembrane protein ‘Her 2 Neu’ is one of the molecular 
bases of breast cancer propagation. Her 2 Neu positivity is found 
in around 18-20% of breast cancer patients and this phenotype 
indicates a more aggressive clinical behavior with early systemic 
metastasis with cranial spread reflecting the worst prognosis 
[2]. The treatment of her 2 Neu positive breast cancer with 
Trastuzumab and anthracycline based chemotherapy is known to 
reduce the rate of loco-regional recurrence by 50% and improve 
survival by nearly 30% [3,4].
However one third of patients with Her 2 Neu positive breast 
cancer will develop central nervous system (CNS) metastasis when 
treated with Trastuzumab as this drug controls extra-cranial disease 
but does not cross the blood brain barrier. We report an interesting case 
of recurrent CNS metastasis in a primary breast carcinoma to bring 
forth important clinical and pathological cues for early diagnosis 
of such cases and to highlight the effect of adequate treatment on 
neurological sequalae and overall prognosis of the patient. 
CASE REPORT
A 43-year-old premenopausal lady, a known case of diabetes since 
2008 had presented in Apr 2011, to the outpatient department due 
to an increasing lump on her left breast. She revealed the history 
of this lump having been present for 2 months. On physical 
examination, a lump located in left upper outer quadrant of size 
2.5 x 2.1 cm was appreciated. The lump was firm, non tender, 
mobile with normal overlying skin. A clinically significant solitary 
left axillary node was also palpable. There was no complaint 
of nipple discharge, no history of trauma and the patient was 
otherwise in good health. She was at clinical stage T2N1Mx 
disease with a biopsy showing histological evidence of invasive 
breast cancer, which was ER +, PR +, and Her 2neu positive on 
immuno-histochemistry. 
Upfront, she underwent a breast conserving surgery with left 
axillary lymph node dissection which on pathological examination 
showed an infiltrating ductal carcinoma with negative margins and 
15 of 16 lymph nodes +++. Her pathological stage was pT2N3a. 
She received adjuvant chemotherapy with Trastuzumab for one 
year including post BCS radiotherapy and hormonal therapy with 
ovarian suppression. The patient remained disease free for 23 
months whereas she presented with headache and visual problems 
and no other deficit. Perimetry confirmed right homonymous 
hemianopia, which reflected towards CNS pathology, confirmed 
as metastatic poorly differentiated adenocarcinoma on histology. 
The growth was ER +, PR -, HER 2neu ++ (IHC) FISH-amplified. 
The patient was administered Trastuzumab beyond progression 
as per standard norms along with chemotherapy with Lapatinib 
and capecetabine. The patient also received holocranial post op 
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radiotherapy 30Gy/ 10# /12 days along with steroids and anti-
epileptic drugs. 
She continued on follow up and remained asymptomatic 
for another 24 months when she again developed headache and 
dizziness in Feb 2015. Neuroimaging showed recurrent CNS 
disease with no extra cranial disease. The MRI showed a left 
occipital region mass of 52x40x37 mm, left Parieto-occipital 
mass of 51x30x40mm size and a few occipital nodules with a 
5.8 mm midline shift (Fig. 1). The repeat PET CT – confirmed a 
Left Occipital lesion with secondary Gliosis and no extra cranial 
disease. It also revealed an atrophic pancreas. The patient was 
admitted for repeat surgery and craniotomy was performed with 
maximal safe tumor resection. (Fig. 2). 
She was managed with steroids, anti-epileptics and antibiotics. 
She continued to be on Inj Trastuzumab with Docetaxel based 
chemo therapy and remained asymptomatic till May 2017. 
Trastuzumab was discontinued, and a third surgical intervention 
to tackle the occipital mass was performed in view of an excellent 
performance status. A newer anti Her2 Neu treatment with a 
drug antibody conjugate (TDM-1) Trastuzumab –Ematsine was 
administered as Lapatinib at a dose of 1250 mg daily. The patient 
continues to remain asymptomatic in ECOG PS01, seizure free 
and is able to carry out her daily activities. She has received nine 
doses of TDM-1 till date and continues to be on follow up.
DISCUSSION
Breast carcinoma involves one third of all cancers in women. It 
is uncommon to have brain metastasis in breast cancer and this 
occurs later in the natural history of the disease with an incidence 
of 10-15% despite treating the primary by surgery followed by 
radiotherapy or chemotherapy. Traditionally metastatic breast 
cancer, without CNS metastasis, has a median survival of 24-36 
months. The aim of treatment is to reduce pain from metastatic 
sites, limit progression and tempo of disease with improvement 
of quality of life with possible improvement in overall survival. 
The median 1-year survival of CNS metastatic breast disease as 
per literature is 20% [5,6 ].
Brain metastasis remains one of the most challenging clinical 
scenarios to tackle in case of a patient with a primary breast 
carcinoma. It is coupled with differential diagnosis including 
astrocytoma, multiple sclerosis, oligodendroglioma, cerebral 
venous thrombosis, CVA and radiation necrosis. Despite extensive 
treatment of the primary, few cases do progress to metastasize 
and it remains a challenge to catch them early and start treatment 
before permanent neurological damage. It is vital that a thorough 
neurological examination be carried in cases of primary breast 
carcinoma to screen for CNS metastasis. Her 2 neu receptors 
are known to be amplified in primary breast carcinoma and is 
involved in the disease’s pathogenesis and pose a poor prognosis 
to women found positive for this mutation. 
Although such cases remain undiagnosed, a few reports 
have been published discussing various modalities of treatment 
and their prognosis. Recent studies have reported cases of 
breast carcinoma with brain metastasis which responded well 
to endocrine therapy including high dose medroxyprogesterone 
acetate with complete resolution of CNS metastasis [7]. Reports 
of middle aged female with secondary’s in brain and scalp on 
letrozole showing complete resolution of neurological symptoms 
and no residual deficit were also recorded [8].
CONCLUSION
This case report highlights the importance of accurate diagnosis 
in patients with persistent headache, continuing anti Her 2 Neu 
treatment beyond progression, aggressive surgical cyto-reduction 
of oligo metastatic disease. Also exploring newer agents 
especially for younger patients with an excellent performance 
status thereby, bringing improved patient survival. 
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